secwatch / observer
8-K filed January 2, 2025, 6:59 PM ET ticker BGLC CIK 0001737523
regulatory confidence high sentiment negative materiality 0.85

BioNexus Gene Lab Corp (BGLC): Nasdaq/NYSE listing notice — BioNexus Gene Lab gets Nasdaq extension to May 1, 2025 for bid price compliance; plans reverse split

BioNexus Gene Lab Corp

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BioNexus Gene Lab Corp received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange
nasdaq
Notice
extension granted
Deficiency
minimum bid price
Rules
5550(a)(2)
Exact text from the filing
December 27, 2024, BioNexus Gene Lab Corp. (the “Company”) received a written notice from the Nasdaq Hearings Panel (the “Panel”) indicating that the Company has been granted a temporary exception to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share (the “Bid Price Rule”). The Company has until May 1, 2025, to regain compliance. As part of this compliance plan, the Company intends to effect a reverse stock split, if necessary, no later than April 7, 2025, and has outlined steps to meet this timeline. Failure to regain compliance by May
View on SEC.gov

Browse all listing & compliance notices →

BioNexus Gene Lab Corp filing history →

Source: SEC EDGAR
accession 0001477932-25-000006
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.